Overview

Putative Cognitive Enhancer VU319

Status:
Completed

Trial end date:
2019-10-30

Target enrollment:

Participant gender:

Summary

This is a safety study of the molecule VU319 to ascertain pharmacokinetic and pharmacodynamic data and test cognitive enhancement in healthy volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Vanderbilt University

Collaborator:

Vanderbilt University Medical Center